查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
铜绿假单胞菌治疗市场：按治疗类型、药剂、给药途径、分销渠道、国家、地区 - 行业分析、市场规模、市场份额、预测 2023-2030
市场调查报告书
商品编码
1290842

铜绿假单胞菌治疗市场：按治疗类型、药剂、给药途径、分销渠道、国家、地区 - 行业分析、市场规模、市场份额、预测 2023-2030

Pseudomonas Aeruginosa Infection Treatment Market with COVID-19 Impact Analysis, By Treatment Type, Drug, Route Of Administration, Distribution channel, Country, & Region-Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
出版日期: | 出版商: AnalystView Market Insights | 英文 389 Pages | 商品交期: 2-3个工作天内

价格

报告要点

2022年铜绿假单胞菌药物市场规模将达到16.078亿美元，2023年至2030年復合年增长率为6.8%

铜绿假单胞菌感染药物市场 - 市场动态

消费者对铜绿假单胞菌治疗的认识不断增强，推动了市场需求

消费者对铜绿假单胞菌治疗的认识的提高肯定会对相关产品和服务的市场需求产生积极影响。消费者意识的提高还可以激发对对抗铜绿假单胞菌的研发工作的兴趣和投资。消费者意识也将导致对支持性护理和患者参与服务的需求增加。对铜绿假单胞菌治疗的需求是由多种因素驱动的，包括铜绿假单胞菌感染患病率的增加和抗生素耐药性的上升。对铜绿假单胞菌血流感染的回顾性分析证实，铜绿假单胞菌 (PA) 导致全世界 10-15% 的医院感染。

铜绿假单胞菌感染治疗市场 - 主要见解

  • 由于可持续增长意识的增强，预计铜绿假单胞菌感染治疗行业将以显着的速度增长
  • 根据治疗细分，预计联合疗法将在 2022 年占据最大的市场份额
  • 按药物类型分，2022年头孢菌素类将成为主要类型
  • 从给药途径来看，2022年以静脉给药为主。
  • 从分销渠道来看，2022年医院是主导类型。
  • 按地区划分，北美为2022年主要收入来源

铜绿假单胞菌感染治疗市场细分分析：

全球铜绿假单胞菌治疗市场根据治疗类型、药物类型、给药途径、分销渠道和区域进行细分。

市场按治疗类型分为三组：单一疗法和联合疗法联合疗法占据市场主导地位。对于治疗严重感染和由多重耐药铜绿假单胞菌引起的感染存在特殊需求。

市场按药物类型分为四类：头孢菌素类、氨基糖甘类、碳青霉烯类、单环内□胺类等。头孢菌素对某些铜绿假单胞菌菌株有效，并且已知这种细菌对许多头孢菌素具有内在耐药性，尤其是第一代头孢菌素。值得一提的是，有

市场按给药途径分为三类：鼻腔、口服和静脉注射。静脉注射在市场上占据主导地位，预计在预测期内将保持其主导地位。这是由于静脉给药途径药物的可用性和给药发生率高。

市场按分销渠道分为三类：医院药房、零售药房和网上药房。医院在市场中占据主导地位，预计在预测期内将保持其主导地位。 医院在铜绿假单胞菌感染的诊断、治疗和预防中发挥着重要作用。我们拥有资源、专业知识和需要有效治疗策略来控制这些感染的患者群体。

铜绿假单胞菌感染治疗市场 - 地理洞察

从地理上看，该市场遍布北美、拉丁美洲、欧洲、亚太地区、中东和非洲。这些地区根据引入业务的国家进一步划分。由于铜绿假单胞菌感染数量不断增加，预计北美将主导铜绿假单胞菌治疗市场的增长。由于合併症增加、导尿管和饲管等侵入性装置的存在、涉及抗生素的多重用药以及与年龄相关的免疫力下降，老年人可能特别容易受到铜绿假单胞菌感染。据美国疾病控制与预防中心称，2017 年，多重耐药铜绿假单胞菌在美国造成约 32,600 例住院感染和约 2,700 人死亡。然而，预计亚太地区和欧洲在预测期内也将为铜绿假单胞菌治疗市场提供显着的增长机会。

铜绿假单胞菌感染治疗市场-竞争格局：

铜绿假单胞菌感染治疗市场竞争激烈，多家製药公司提供抗生素和其他治疗方案来对抗这些感染。製药公司通过企业网站、电子商务网站、零售商、分销商和最终消费者等多种渠道参与治疗铜绿假单胞菌感染的抗生素的开发和营销。此外，开发新抗生素和联合疗法来对抗铜绿假单胞菌新出现的耐药性的能力对于在该市场保持竞争力至关重要。例如，Pfizer将于 2023 年将 SPR-206 投入临床开发，目前正处于治疗铜绿假单胞菌感染的 I 期临床阶段。根据Global Data的数据，针对铜绿假单胞菌的I期药物的相变成功率（PTSR）为67%，这是进入II期的标誌。

最近的发展

Allergan最近宣布，美国食品和药物管理局(FDA) 已批准AVYCAZ（头孢他啶和阿维巴坦）用于治疗复杂性尿路感染(cUTI)，并宣布已收到寻求扩大治疗适应症的补充新药申请(sNDA)复杂性腹腔内感染（cIAI）。

研究的主要特点

  • 本研究报告以2022年为基准年，提供了铜绿假单胞菌治疗市场的市场规模、复合年增长率、估计和预测（2023-2030年）。
  • 该研究报告为客户提供了铜绿假单胞菌治疗市场的最新进展和见解。
  • 该研究报告阐明了不同细分市场/国家的潜在增长机会，并说明了铜绿假单胞菌感染治疗市场有吸引力的投资主张矩阵。
  • 它确定了铜绿假单胞菌治疗市场的新兴投资机会、现有企业面临的挑战以及持续增长动力。
  • 研究报导详细讨论了 COVID-19 对铜绿假单胞菌感染治疗市场规模、预测、复合年增长率和市场动态的影响。还涵盖了对新冠肺炎后铜绿假单胞菌治疗市场的深入见解。
  • 为了向本报告的用户提供铜绿假单胞菌感染治疗市场的全面了解，我们还包括了铜绿假单胞菌感染治疗市场的竞争格局和关键创新者分析。
  • 该研究涵盖了基于市场规模、增长率和吸引力对所有行业领域进行基准测试的增长前景映射分析。
  • 提供主要市场进入者的详细公司概况，以帮助您了解在铜绿假单胞菌治疗市场运营的公司的财务信息和战略举措。
  • 此外，报告还揭示了市场主要进入者不仅在全球层面而且在区域层面的重大收购和兼併、联盟和合资企业、新产品推出、研发和区域扩张。
  • 全球铜绿假单胞菌治疗市场报告主要面向该行业的各个利益相关者，如供应商、投资者、新进入者、分销商和财务分析师。

目录

第一章 铜绿假单胞菌感染治疗市场概述

  • 调查范围

第二章执行摘要

  • 市场细分
  • 竞争考虑

第三章铜绿假单胞菌感染治疗的主要市场趋势

  • 铜绿假单胞菌治疗市场驱动因素
  • 铜绿假单胞菌治疗市场製约因素
  • 铜绿假单胞菌药物的市场机会
  • 铜绿假单胞菌药物市场的未来趋势

第四章 铜绿假单胞菌感染治疗行业调查

  • PEST分析
  • 波特五力分析
  • 绘製增长前景
  • 监管框架分析

第五章铜绿假单胞菌感染治疗市场：COVID-19 的影响分析

  • COVID-19 之前的影响分析
  • COVID-19 后影响分析

第六章 铜绿假单胞菌感染治疗市场格局

  • 2022 年铜绿假单胞菌治疗市场份额分析
  • 主要製造商的细分数据
    • 已成立公司分析
    • 启动分析

7. 铜绿假单胞菌感染治疗市场 - 按药物类型

  • 概述
    • 按药品类型划分的细分市场份额分析
    • 头孢类
    • 氨基糖甘类
    • 碳青霉烯类
    • 内□胺
    • 其他

8. 铜绿假单胞菌感染治疗市场-按给药途径分类

  • 概述
    • 按给药途径划分的细分市场份额分析
    • 鼻子
    • 口服
    • 静脉

9. 铜绿假单胞菌感染治疗市场-按分销渠道

  • 概述
    • 按销售渠道划分的细分市场份额分析
    • 医院药房
    • 零售药店
    • 网上药店

10 铜绿假单胞菌感染治疗市场 – 按地区

  • 介绍
  • 北美
    • 概述
    • 铜绿假单胞菌感染性药物北美主要製造商
    • 美国
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲主要铜绿假单胞菌药物製造商
    • 德国
    • 意大利
    • 英国
    • 法国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 其他
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区铜绿假单胞菌药物主要生产商
    • 印度
    • 中国
    • 日本
    • 韩国
    • 澳大利亚
    • 泰国
    • 印度尼西亚
    • 菲律宾
    • 其他
  • 拉丁美洲
    • 概述
    • 拉丁美洲一家主要的铜绿假单胞菌药物製造商
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 其他
  • 中东和非洲
    • 概述
    • 中东和非洲铜绿假单胞菌药品主要生产商
    • 沙特阿拉伯
    • 阿拉伯联合酋长国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • 其他

11.主要供应商分析-铜绿假单胞菌处理行业

  • 比赛仪表板
  • 公司简介
    • Allergan
    • Pfizer Inc.
    • Merck & Co. Inc.
    • AstraZeneca PLC
    • Novartis AG
    • Lupin Pharmaceuticals Inc.
    • EnBiotix Inc
    • Teva Pharmaceutical Industries Ltd.
    • Bristol-Myers Squibb Co.
    • Humanigen Inc
    • 其他

第十二章 分析师的全面看法

Product Code: ANV1288

REPORT HIGHLIGHT

Pseudomonas aeruginosa infection treatment Market size was valued at USD 1,607.8 million in 2022, expanding at a CAGR of 6.8% from 2023 to 2030.

Pseudomonas aeruginosa infections are generally treated with antibiotics. However, due to the bacterium's ability to develop resistance, selecting appropriate antibiotics can be challenging. Pseudomonas aeruginosa has been known to develop resistance to various antibiotics, an including those commonly used to treat infections. However, certain antibiotics, such as polymyxins can still be effective against multidrug-resistant strains. Additionally, newer antibiotics and alternative therapies, such as bacteriophages and monoclonal antibodies, are being explored as potential treatment options for multidrug-resistant Pseudomonas aeruginosa infections.

Pseudomonas aeruginosa infection treatment Market- Market Dynamics

Increasing consumer awareness about Pseudomonas aeruginosa infection treatment to propel market demand

Increasing consumer awareness about Pseudomonas aeruginosa infection treatment can certainly have a positive impact on market demand for related products and services. increasing consumer awareness can also adoptive interest and investment in research and development efforts to combat Pseudomonas aeruginosa infections. Consumer awareness can also lead to increased demand for supportive care and patient engagement services. The demand for Pseudomonas aeruginosa infection treatment is driven by several factors, including the increasing prevalence of Pseudomonas aeruginosa infections, rising antibiotic resistance, and others. A retrospective analysis of Pseudomonas aeruginosa bloodstream infections identified that Pseudomonas aeruginosa (PA) is responsible for 10-15% of nosocomial infections worldwide.

Pseudomonas aeruginosa infection treatment Market- Key Insights

  • As per the analysis shared by our research analyst, the global Pseudomonas aeruginosa infection treatment market is estimated to grow annually at a CAGR of around XX% over the forecast period (2023-2030)
  • The Pseudomonas aeruginosa infection treatment industry is projected to grow at a significant rate due to the growing awareness of sustainable growth
  • Based on treatment segmentation, Combination Therapy was predicted to show maximum market share in the year 2022
  • Based on drug type segmentation, Cephalosporin was the leading type in 2022
  • Based on Route of Administration segmentation, Intravenous was the leading type in 2022
  • Based on distribution channels segmentation, Hospitals was the leading type in 2022
  • On the basis of region, North America was the leading revenue generator in 2022

Pseudomonas aeruginosa infection treatment Market- Segmentation Analysis:

The Global Pseudomonas aeruginosa infection treatment Market is segmented on the basis of treatment type, drug type, route of administration, distribution channel, and Region.

The market is divided into three categories based on treatment type: Monotherapy and Combination Therapy. Combination Therapy dominates the market. It is particularly in demand for the treatment of severe infections or infections caused by multidrug-resistant strains of Pseudomonas aeruginosa.

The market is divided into four categories based on drug type: Cephalosporin, Aminoglycoside, Carbapenem, Monobactam, and Others. Cephalosporin propels market growth, due to It can be effective against certain strains of Pseudomonas aeruginosa, it's worth mentioning that this bacterium is known to be inherently resistant to many cephalosporin's, especially the first-generation cephalosporin's.

The market is divided into three categories based on the Route of Administration: Nasal, Oral, and Intravenous. Intravenous dominates the market and is likely to maintain its dominance during the forecast period, due to the availability of drugs for the Intravenous route, and high occurrence in dosing.

The market is divided into three categories based on distribution channels: Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. Hospitals dominate the market and are likely to maintain their dominance during the forecast period. It plays a crucial role in diagnosing, treating, and preventing Pseudomonas aeruginosa infections. They have the resources, expertise, and patient population that necessitate effective treatment strategies for managing these infections.

Pseudomonas aeruginosa infection treatment Market- Geographical Insights

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to dominate the growth of the Pseudomonas aeruginosa infection treatment Market, due to a rise in the number of Pseudomonas aeruginosa infections. The elderly population may be particularly disposed to pseudomonad infection as a result of increased co-morbidities, the presence of invasive devices such as urinary catheters and feeding tubes, and polypharmacy that includes antibacterial, and immune compromise related to age. According to the center for disease control and Prevention, in 2017, multidrug-resistant Pseudomonas aeruginosa caused an estimated 32,600 infections among hospitalized patients and 2,700 estimated deaths in the United States. However, Asia Pacific and Europe are also expected to offer substantial growth opportunities for the Pseudomonas aeruginosa infection treatment market during the forecast period.

Pseudomonas aeruginosa infection treatment Market- Competitive Landscape:

The treatment market for Pseudomonas aeruginosa infections is competitive, with several pharmaceutical companies offering antibiotics and other therapeutic options to combat these infections. pharmaceutical companies involved in the development and marketing of antibiotics for Pseudomonas aeruginosa infections through a variety of channels, including corporate websites, e-commerce websites, retailers, distributors, and end consumers. Additionally, the ability to develop new antibiotics or combination therapies to address emerging drug resistance in Pseudomonas aeruginosa is crucial for maintaining competitiveness in this market. For example, in 2023, SPR-206 is under clinical development by Pfizer and is currently in Phase I for Pseudomonas aeruginosa Infections. According to Global Data, Phase I drugs for Pseudomonas aeruginosa Infections has a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase II.

Recent Developments:

Allergan plc recently announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's supplemental New Drug Application (sNDA) for AVYCAZ (ceftazidime and avibactam), seeking to expand the label to include the treatment of complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI), in combination with metronidazole, in pediatric patients 3 months to less than 18 years of age.

Key features of the study:

  • This proposed research study on Pseudomonas aeruginosa infection treatment market provides market size (US$ million), compound annual growth rate (CAGR %) and forecast estimation (2023-2030), considering 2022 as the base year
  • The report provides the client the latest up-to-date and trending insights about the Pseudomonas aeruginosa infection treatment market.
  • The research report elucidates potential growth opportunities across different segments/countries and explains attractive investment proposition matrix for Pseudomonas aeruginosa infection treatment market
  • The overall report identifies new investment opportunities, challenges faced by established players, and growth factors to sustain in the Pseudomonas aeruginosa infection treatment market
  • Impact of COVID-19 on Pseudomonas aeruginosa infection treatment market size, forecast, CAGR, and market dynamics are discussed in detail under the research scope. Detailed insight on Pseudomonas aeruginosa infection treatment market post-COVID will also be covered.
  • In order to give the users of this report a comprehensive view on the Pseudomonas aeruginosa infection treatment market, we have also included competitive landscape and key innovator analysis for the Pseudomonas aeruginosa infection treatment market.
  • The study encompasses a growth prospect mapping analysis, wherein all the industry segments are benchmarked based on their market size, growth rate and attractiveness.
  • The report offers detailed company profiling featuring major market participants which will help users to understand their financial information and strategic initiatives of players operating in the Pseudomonas aeruginosa infection treatment market.
  • In addition, the report also unveil the important acquisitions & mergers, collaborations & joint ventures, new launch, research & development, regional expansion of major participants involved in the market on global as well as regional level.
  • The global Pseudomonas aeruginosa infection treatment market report primarily caters to various stakeholders in this industry including suppliers, investors, new entrants, distributors, and financial analysts

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET KEY PLAYERS

  • Allergan
  • Pfizer Inc.
  • Merck & Co. Inc.
  • AstraZeneca PLC
  • Novartis AG
  • Lupin Pharmaceuticals Inc.
  • EnBiotix Inc
  • Teva Pharmaceutical Industries Ltd.
  • Bristol-Myers Squibb Co.
  • Humanigen Inc
  • Other

GLOBAL PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY TREATMENT TYPE

  • Monotherapy
  • Combination Therapy

GLOBAL PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY DRUG TYPE

  • Cephalosporin
  • Aminoglycoside
  • Carbapenem
  • Monobactam
  • Others

GLOBAL PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

  • Nasal
  • Oral
  • Intravenous

GLOBAL PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY DISTRIBUTION CHANNEL

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

GLOBAL PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY REGION

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

TABLE OF CONTENT

1. Pseudomonas aeruginosa infection treatment Market Overview

  • 1.1. Study Scope

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Pseudomonas aeruginosa infection treatment Market Snippet by Drug Type
    • 2.1.2. Pseudomonas aeruginosa infection treatment Market Snippet by Route of Administration
    • 2.1.3. Pseudomonas aeruginosa infection treatment Market Snippet by Distribution channels
    • 2.1.4. Pseudomonas aeruginosa infection treatment Market Snippet by Country
    • 2.1.5. Pseudomonas aeruginosa infection treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Pseudomonas aeruginosa infection treatment Key Market Trends

  • 3.1. Pseudomonas aeruginosa infection treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Pseudomonas aeruginosa infection treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Pseudomonas aeruginosa infection treatment Market Opportunities
  • 3.4. Pseudomonas aeruginosa infection treatment Market Future Trends

4. Pseudomonas aeruginosa infection treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Pseudomonas aeruginosa infection treatment Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Pseudomonas aeruginosa infection treatment Market Landscape

  • 6.1. Pseudomonas aeruginosa infection treatment Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Pseudomonas aeruginosa infection treatment Market - By Drug Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Type, 2022 & 2030 (%)
    • 7.1.2. Cephalosporin
    • 7.1.3. Aminoglycoside
    • 7.1.4. Carbapenem
    • 7.1.5. Monobactam
    • 7.1.6. Others

8. Pseudomonas aeruginosa infection treatment Market - By Route of Administration

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Route of Administration, 2022 & 2030 (%)
    • 8.1.2. Nasal
    • 8.1.3. Oral
    • 8.1.4. Intravenous

9. Pseudomonas aeruginosa infection treatment Market - By Distribution channels

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution channels, 2022 & 2030 (%)
    • 9.1.2. Hospital Pharmacy
    • 9.1.3. Retail Pharmacy
    • 9.1.4. Online Pharmacy

10. Pseudomonas aeruginosa infection treatment Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Pseudomonas aeruginosa infection treatment Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Pseudomonas aeruginosa infection treatment Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Pseudomonas aeruginosa infection treatment Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Pseudomonas aeruginosa infection treatment Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Pseudomonas aeruginosa infection treatment Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)

11. Key Vendor Analysis- Pseudomonas aeruginosa infection treatment Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Allergan
    • 11.2.2. Pfizer Inc.
    • 11.2.3. Merck & Co. Inc.
    • 11.2.4. AstraZeneca PLC
    • 11.2.5. Novartis AG
    • 11.2.6. Lupin Pharmaceuticals Inc.
    • 11.2.7. EnBiotix Inc
    • 11.2.8. Teva Pharmaceutical Industries Ltd.
    • 11.2.9. Bristol-Myers Squibb Co.
    • 11.2.10. Humanigen Inc
    • 11.2.11. Other

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Pseudomonas aeruginosa infection treatment Market: Drug Type Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Drug Type
  • TABLE Global Pseudomonas aeruginosa infection treatment Market, by Drug Type 2018-2030 (USD Million)
  • TABLE Pseudomonas aeruginosa infection treatment Market: Route of Administration Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Route of Administration
  • TABLE Global Pseudomonas aeruginosa infection treatment Market, by Route of Administration 2018-2030 (USD Million)
  • TABLE Pseudomonas aeruginosa infection treatment Market: Regional snapshot (2022)
  • TABLE Pseudomonas aeruginosa infection treatment Market: Distribution channels Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Distribution channels
  • TABLE Global Pseudomonas aeruginosa infection treatment Market, by Distribution channels 2018-2030 (USD Million)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Pseudomonas aeruginosa infection treatment Market, by Region 2018-2030 (USD Million)
  • TABLE North America Pseudomonas aeruginosa infection treatment Market, by Country, 2018-2030 (USD Million)
  • TABLE North America Pseudomonas aeruginosa infection treatment Market, by Drug Type, 2018-2030 (USD Million)
  • TABLE North America Pseudomonas aeruginosa infection treatment Market, by Route of Administration, 2018-2030 (USD Million)
  • TABLE North America Pseudomonas aeruginosa infection treatment Market, by Distribution channels, 2018-2030 (USD Million)
  • TABLE Europe Pseudomonas aeruginosa infection treatment Market, by Country, 2018-2030 (USD Million)
  • TABLE Europe Pseudomonas aeruginosa infection treatment Market, by Drug Type, 2018-2030 (USD Million)
  • TABLE Europe Pseudomonas aeruginosa infection treatment Market, by Route of Administration, 2018-2030 (USD Million)
  • TABLE Europe Pseudomonas aeruginosa infection treatment Market, by Distribution channels, 2018-2030 (USD Million)
  • TABLE Asia Pacific Pseudomonas aeruginosa infection treatment Market, by Country, 2018-2030 (USD Million)
  • TABLE Asia Pacific Pseudomonas aeruginosa infection treatment Market, by Drug Type, 2018-2030 (USD Million)
  • TABLE Asia Pacific Pseudomonas aeruginosa infection treatment Market, by Route of Administration, 2018-2030 (USD Million)
  • TABLE Asia Pacific Pseudomonas aeruginosa infection treatment Market, by Distribution channels, 2018-2030 (USD Million)
  • TABLE Latin America Pseudomonas aeruginosa infection treatment Market, by Country, 2018-2030 (USD Million)
  • TABLE Latin America Pseudomonas aeruginosa infection treatment Market, by Drug Type, 2018-2030 (USD Million)
  • TABLE Latin America Pseudomonas aeruginosa infection treatment Market, by Route of Administration, 2018-2030 (USD Million)
  • TABLE Latin America Pseudomonas aeruginosa infection treatment Market, by Distribution channels, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Pseudomonas aeruginosa infection treatment Market, by Country, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Pseudomonas aeruginosa infection treatment Market, by Drug Type, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Pseudomonas aeruginosa infection treatment Market, by Route of Administration, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Pseudomonas aeruginosa infection treatment Market, by Distribution channels, 2018-2030 (USD Million)